During the past decade, CHU Charleroi conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 8 clinical trials were completed, i.e. on average, 28.6% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 6 clinical trials were completed. i.e. 120% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU Charleroi" #1 sponsor was "Henogen" with 4 trials, followed by "Boehringer Ingelheim" with 3 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "Medtronic Vascular" with 3 trials sponsored and "The Lymphoma Academic Research Organisation" with 3 trials sponsored. Other sponsors include 30 different institutions and companies that sponsored additional 35 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU Charleroi" #1 collaborator was "GlaxoSmithKline" with 3 trials as a collaborator, "Centre Hospitalier Universitaire de Charleroi" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Agentschap voor Innovatie door Wetenschap en Technologie" with 1 trials as a collaborator and "Barmherzige Brüder Vienna" with 1 trials as a collaborator. Other collaborators include 51 different institutions and companies that were collaborators in the rest 61 trials.

According to Clinical.Site data, the most researched conditions in "CHU Charleroi" are "Coronary Artery Disease" (8 trials), "Hepatitis B" (4 trials), "Chronic Obstructive Pulmonary Disease" (2 trials), "Heart Failure" (2 trials) and "Myocardial Ischemia" (2 trials). Many other conditions were trialed in "CHU Charleroi" in a lesser frequency.

Most popular intervention types in "CHU Charleroi" are "Drug" (22 trials), "Device" (12 trials), "Procedure" (9 trials), "Biological" (4 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Azithromycin" (2 trials), "Empagliflozin" (2 trials), "HBVAXPRO vaccine" (2 trials) and "Ocrelizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "CHU Charleroi" are 49 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "CHU Charleroi". undefined are not yet recruiting, 5 are recruiting, 6 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 29 completed trials in CHU Charleroi, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in CHU Charleroi, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 13 trials that are defined as “Not Applicable".

CHU Charleroi has several departments that took part in Clinical trials: "Department of Pneumology CHU Charleroi" - 6 trials